Black patients are still underrepresented in most trials relating to approval of new drugs, despite implementation of an action plan in 2015 to improve diversity, according to a report published in the March issue of Health Affairs.
Black patients still underrepresented in trials for new drug approvals
Black patients are still underrepresented in most trials relating to approval of new drugs, despite implementation of an action plan in 2015 to improve diversity, according to a report published in the March issue of Health Affairs.